1-20 of 57
lenalidomide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.
https://doi.org/10.1182/hematology.2019000075
Published: 2019
Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.
https://doi.org/10.1182/hematology.2019000032
Published: 2019
Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.
https://doi.org/10.1182/hematology.2019000011
Published: 2019
Journal Articles

Treatments targeting MDS genetics: a fool’s errand?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 277–285.
https://doi.org/10.1182/asheducation-2018.1.277
Published: 2018
Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.
https://doi.org/10.1182/asheducation-2018.1.194
Published: 2018
Journal Articles

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Saad Z. Usmani, Eric Seifter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 97–102.
https://doi.org/10.1182/asheducation-2018.1.97
Published: 2018
Journal Articles

Current treatment algorithm for the management of lower-risk MDS

Aristoteles Giagounidis
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 453–459.
https://doi.org/10.1182/asheducation-2017.1.453
Published: 2017
Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.
https://doi.org/10.1182/asheducation-2017.1.212
Published: 2017
Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.
https://doi.org/10.1182/asheducation-2017.1.508
Published: 2017
Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.
https://doi.org/10.1182/asheducation-2016.1.485
Published: 2016
Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.
https://doi.org/10.1182/asheducation-2016.1.495
Published: 2016
Journal Articles

Treatment of low-risk myelodysplastic syndromes

Valeria Santini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 462–469.
https://doi.org/10.1182/asheducation-2016.1.462
Published: 2016
Journal Articles

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Hetty E. Carraway
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 470–477.
https://doi.org/10.1182/asheducation-2016.1.470
Published: 2016
Journal Articles

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Philip L. McCarthy, Sarah A. Holstein
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 504–511.
https://doi.org/10.1182/asheducation.V2016.1.504.088352
Published: 2016
Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.
https://doi.org/10.1182/asheducation-2015.1.279
Published: 2015
Journal Articles

Novel combination approaches for myeloma

Sagar Lonial, Ajay K. Nooka
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 286–293.
https://doi.org/10.1182/asheducation-2015.1.286
Published: 2015
Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.
https://doi.org/10.1182/asheducation-2015.1.308
Published: 2015
Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.
https://doi.org/10.1182/asheducation-2014.1.82
Published: 2014
Journal Articles

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 255–261.
https://doi.org/10.1182/asheducation-2014.1.255
Published: 2014
Journal Articles

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 1–7.
https://doi.org/10.1182/asheducation-2014.1.1
Published: 2014